Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corporation (Nasdaq: DERM) is a commercial-stage pharmaceutical company that focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. The company reports that it currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions, and it is based in Scottsdale, Arizona.
The news flow around Journey Medical often centers on its dermatology portfolio and, in particular, Emrosi (DFD-29), an FDA-approved low-dose oral minocycline formulation indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Company press releases highlight clinical trial milestones, such as pooled Phase 3 efficacy analyses demonstrating statistical superiority of DFD-29 versus placebo and an active comparator, as well as Phase 1 data published in the Journal of Drugs in Dermatology showing no detectable impact on skin, gastrointestinal or vaginal microbiota over 16 weeks in healthy adults.
Investors following DERM news can also expect updates on quarterly financial results, revenue trends, and the commercial performance of Emrosi and other branded dermatology products. Journey Medical regularly issues releases on its net product revenues, gross margin metrics, and developments such as expanded payer access for Emrosi and inclusion in the Russell 2000 and Russell 3000 indices. Additional news items may cover corporate events, investor conference participation, credit agreement amendments, and capital markets activities disclosed through SEC filings and press announcements.
This news page aggregates Journey Medical’s press releases and related coverage so readers can review developments in its dermatology product portfolio, clinical data presentations, and public company updates in one place.
Journey Medical Corporation (NASDAQ: DERM) has expanded its board of directors, admitting four new independent members: Jeffrey Paley, M.D., Justin Smith, Miranda Toledano, and Neil Herskowitz. This strategic move supports the company following its recent IPO. Executive Chairman Lindsay Rosenwald emphasized the new board members' extensive expertise in finance and dermatology, aiming to drive growth and commercialization of dermatological products. Journey Medical currently has seven marketed products and one in clinical development, indicating potential for future expansion.
Journey Medical Corporation (NASDAQ: DERM) has closed its initial public offering, successfully selling 3,520,000 shares at $10.00 each, raising gross proceeds of $35.2 million. The proceeds will be allocated towards general corporate purposes, including research and development, marketing, and potential acquisitions. The offering was managed by B. Riley Securities, with Roth Capital Partners as a co-manager. Journey Medical specializes in dermatological products and aims to leverage its capital for growth in the competitive pharmaceutical market.
Journey Medical Corporation (NASDAQ: DERM) has priced its initial public offering (IPO) at $10 per share, raising gross proceeds of $35.2 million. The company, a subsidiary of Fortress Biotech (NASDAQ: FBIO), will receive approximately $31.4 million in net proceeds after expenses. The IPO is set to close on November 16, 2021, with common stock starting to trade on November 12, 2021. Proceeds will support working capital, R&D, marketing, and potential acquisitions.
Journey Medical Corporation has launched an initial public offering (IPO) of 3,200,000 shares of common stock, expected to price between $10 and $12 per share. The company, a subsidiary of Fortress Biotech (FBIO), may also allow underwriters to purchase an additional 480,000 shares. Journey Medical aims to list its shares on The Nasdaq Capital Market under the symbol ‘DERM.’ B. Riley Securities is the sole book-running manager, with Roth Capital Partners as a co-manager. The offering is subject to market conditions and regulatory approval.